NCT06835296View on ClinicalTrials.gov

A Study of Oral YUQ-A1007 in Healthy Volunteers

PHASE1RecruitingINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

March 20, 2025

Primary Completion Date

August 30, 2025

Study Completion Date

November 30, 2025

Conditions
Healthy
Interventions
DRUG

YUQ-A1007 is a novel gut-enriched AhR agonist. This compound is undergoing preclinical development, and comprehensive nonclinical studies.

Dose: Ascending doses (SAD stage: 200, 800, 1600, or 3200 mg; MAD stage: two dosages will be determined based on the results from the SAD stage) Mode of administration: Oral, once daily.

Trial Locations (1)

92801

RECRUITING

Anaheim Clinical Trials, Anaheim

All Listed Sponsors
lead

Allianthera (Suzhou) Biopharmaceuticals Co., Ltd.

INDUSTRY

NCT06835296 - A Study of Oral YUQ-A1007 in Healthy Volunteers | Biotech Hunter | Biotech Hunter